Efficacy and Safety of 500mg of Fulvestrant
Fulvestrant has proven effective in the treatment of hormone receptor positive metastatic breast cancer. The dose used in studies so far has been well tolerated and may be too low for optimal effectiveness. In this study, a higher dose will be used to see whether an improved outcome will result.
Breast Cancer
DRUG: Fulvestrant
To assess the clinical benefit rate for subjects receiving this dose and schedule of fulvestrant.
Overall objective response rate, time to response, duration of response, duration of clinical benefit, and time to progression.|Assessment of adverse events, 4 years|Assessment of pharmacokinetics of this dose and schedule of fulvestrant., 4 years
* Fulvestrant will be administered by intramuscular injection on day 1, day 15 and day 29 and then every 28 days thereafter.
* Participants will have a physical examination and blood work performed on each treatment date. After teh study treatment has been completed, the physical examinations will be done every three months for the first 2 years, every 6 months for years 2-5, and annually after 5 years.
* Participants may remain on study treatment until disease progression or until they experience serious side effects.